Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.
We assessed initial clinical experience with IV tissue plasminogen activator (t-PA) treatment of acute ischemic stroke in a standardized retrospective survey of hospitals with experienced acute stroke treatment systems. The incidence of symptomatic intracerebral hemorrhage (ICH) was 6% (11 of 189 patients; 95% CI 3 to 11%), similar to that in the National Institute of Neurological Disorders and Stroke (NINDS) t-PA Stroke Study. Deviations from the NINDS protocol guidelines were identified in 30% of patients (56 of 189). The incidence of symptomatic ICH was 11% among patients with protocol deviations as compared with 4% in patients who were treated according to the NINDS protocol guidelines, suggesting that strict adherence to protocol guidelines is prudent.
Tanne
D
D
Henry Ford Hospital and Health Science Center, Detroit, MI, USA.
Bates
V E
VE
Verro
P
P
Kasner
S E
SE
Binder
J R
JR
Patel
S C
SC
Mansbach
H H
HH
Daley
S
S
Schultz
L R
LR
Karanjia
P N
PN
Scott
P
P
Dayno
J M
JM
Vereczkey-Porter
K
K
Benesch
C
C
Book
D
D
Coplin
W M
WM
Dulli
D
D
Levine
S R
SR
D000368:Aged; D002545:Brain Ischemia / Q000628:therapy*; D002561:Cerebrovascular Disorders / Q000628:therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010959:Tissue Plasminogen Activator